Investigational Drug Information for AZD4635
✉ Email this page to a colleague
What is the drug development status for AZD4635?
AZD4635 is an investigational drug.
There have been 7 clinical trials for AZD4635.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 29th 2019.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, Parexel, and MedImmune LLC.
There are three US patents protecting this investigational drug and thirty-one international patents.
Summary for AZD4635
| US Patents | 3 |
| International Patents | 31 |
| US Patent Applications | 42 |
| WIPO Patent Applications | 29 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2019-08-29) |
| Vendors | 45 |
Recent Clinical Trials for AZD4635
| Title | Sponsor | Phase |
|---|---|---|
| A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. | Parexel | Phase 2 |
| A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. | AstraZeneca | Phase 2 |
| A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers | Parexel | Phase 1 |
Clinical Trial Summary for AZD4635
Top disease conditions for AZD4635
Top clinical trial sponsors for AZD4635
US Patents for AZD4635
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD4635 | ⤷ Sign Up | 1,2,4-triazine-4-amine derivatives | Heptares Therapeutics Limited (Welwyn Garden, GB) | ⤷ Sign Up |
| AZD4635 | ⤷ Sign Up | 1,2,4-triazine-4-amine derivatives | Heptares Therapeutics Limited (Hertfordshire, GB) | ⤷ Sign Up |
| AZD4635 | ⤷ Sign Up | 1,2,4-triazine-4-amine derivatives | Heptares Therapeutics Limited (Hertfordshire, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD4635
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD4635 | Australia | AU2011212430 | 2030-02-05 | ⤷ Sign Up |
| AZD4635 | Brazil | BR112012019540 | 2030-02-05 | ⤷ Sign Up |
| AZD4635 | Canada | CA2789279 | 2030-02-05 | ⤷ Sign Up |
| AZD4635 | China | CN102822150 | 2030-02-05 | ⤷ Sign Up |
| AZD4635 | Cyprus | CY1117780 | 2030-02-05 | ⤷ Sign Up |
| AZD4635 | Denmark | DK2531492 | 2030-02-05 | ⤷ Sign Up |
| AZD4635 | European Patent Office | EP2531492 | 2030-02-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
